BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 1761450)

  • 1. Dosage adjustment and clinical outcomes of long-term use of high-dose tobramycin in adult cystic fibrosis patients.
    Li SC; Bowes G; Ioannides-Demos LL; Spicer WJ; Hooper RE; Spelman DW; Tong N; McLean AJ
    J Antimicrob Chemother; 1991 Oct; 28(4):561-8. PubMed ID: 1761450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis.
    Vic P; Ategbo S; Turck D; Husson MO; Launay V; Loeuille GA; Sardet A; Deschildre A; Druon D; Arrouet-Lagande C
    Arch Dis Child; 1998 Jun; 78(6):536-9. PubMed ID: 9713009
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of once daily tobramycin in cystic fibrosis--caution with trough concentrations.
    Coulthard KP; Peckham DG; Conway SP; Smith CA; Bell J; Turnidge J
    J Cyst Fibros; 2007 Apr; 6(2):125-30. PubMed ID: 16829216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing dosage adjustment methods for once-daily tobramycin in paediatric and adolescent patients with cystic fibrosis.
    Hennig S; Holthouse F; Staatz CE
    Clin Pharmacokinet; 2015 Apr; 54(4):409-21. PubMed ID: 25403847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
    Smyth A; Tan KH; Hyman-Taylor P; Mulheran M; Lewis S; Stableforth D; Prof Knox A;
    Lancet; 2005 Feb 12-18; 365(9459):573-8. PubMed ID: 15708100
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy, safety, and local pharmacokinetics of highly concentrated nebulized tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa.
    Lenoir G; Antypkin YG; Miano A; Moretti P; Zanda M; Varoli G; Monici Preti PA; Aryayev NL
    Paediatr Drugs; 2007; 9 Suppl 1():11-20. PubMed ID: 17536871
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
    Horrevorts AM; de Witte J; Degener JE; Dzoljic-Danilovic G; Hop WC; Driessen O; Michel MF; Kerrebijn KF
    Chest; 1987 Nov; 92(5):844-8. PubMed ID: 3665599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of high-dose tobramycin-carbenicillin therapy in pseudomonal infections in cystic fibrosis.
    Fraser GL; Valenti AJ; Grimes GR; Corbin RP
    Drug Intell Clin Pharm; 1985 Oct; 19(10):757-61. PubMed ID: 4053983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal tobramycin dosage in patients with cystic fibrosis--evidence for predictability based on previous drug monitoring.
    Bartel K; Habash T; Lugauer S; Bärmeier H; Böwing B; Unsal M; Schoerner C; Heininger U
    Infection; 1999; 27(4-5):268-71. PubMed ID: 10885841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of a Once/Day Tobramycin Regimen to Achieve Target Concentrations in Adult Patients with Cystic Fibrosis.
    Staubes BA; Metzger NL; Walker SD; Peasah SK
    Pharmacotherapy; 2016 Jun; 36(6):623-30. PubMed ID: 27138730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis.
    Jackson MA; Kusmiesz H; Shelton S; Prestidge C; Kramer RI; Nelson JD
    Pediatr Infect Dis; 1986; 5(4):440-3. PubMed ID: 3725655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.
    Barras MA; Serisier D; Hennig S; Jess K; Norris RL
    Antimicrob Agents Chemother; 2016 Nov; 60(11):6698-6702. PubMed ID: 27572411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A; Csiszér E; Gyurkovics K; Bartnicka MT; Sands D; Kapranov N; Varoli G; Monici Preti PA; Mazurek H
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin ototoxicity. Repeated courses of high dosage treatment in children with cystic fibrosis.
    Thomsen J; Friis B; Jensen K; Bak-Pedersen K; Larsen PK
    J Antimicrob Chemother; 1979 May; 5(3):257-60. PubMed ID: 479061
    [No Abstract]   [Full Text] [Related]  

  • 16. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides.
    Young DC; Zobell JT; Stockmann C; Waters CD; Ampofo K; Sherwin CM; Spigarelli MG
    Pediatr Pulmonol; 2013 Nov; 48(11):1047-61. PubMed ID: 24000183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
    Ramsey BW; Pepe MS; Quan JM; Otto KL; Montgomery AB; Williams-Warren J; Vasiljev-K M; Borowitz D; Bowman CM; Marshall BC; Marshall S; Smith AL
    N Engl J Med; 1999 Jan; 340(1):23-30. PubMed ID: 9878641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative and acute toxicity of repeated high-dose tobramycin treatment in cystic fibrosis.
    Pedersen SS; Jensen T; Osterhammel D; Osterhammel P
    Antimicrob Agents Chemother; 1987 Apr; 31(4):594-9. PubMed ID: 3606063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis.
    Touw DJ; Vinks AA; Heijerman HG; Hermans J; Bakker W
    Ther Drug Monit; 1994 Apr; 16(2):125-31. PubMed ID: 8009558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and safety of an 8 week continuous treatment with once-daily versus twice-daily inhalation of tobramycin in cystic fibrosis patients.
    van Koningsbruggen-Rietschel S; Heuer HE; Merkel N; Posselt HG; Staab D; Sieder C; Ziegler J; Krippner F; Rietschel E
    J Antimicrob Chemother; 2016 Mar; 71(3):711-7. PubMed ID: 26626719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.